Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-01-11
2005-01-11
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S417000
Reexamination Certificate
active
06841567
ABSTRACT:
The present invention is directed to cyclic substituted fused pyrrolocarbazoles and isoindolones. The invention also is directed to methods for making and using the cyclic substituted fused pyrrolocarbazoles and isoindolones.
REFERENCES:
patent: 4735939 (1988-04-01), McCoy et al.
patent: 4816450 (1989-03-01), Bell et al.
patent: 4877776 (1989-10-01), Murakata et al.
patent: 4923986 (1990-05-01), Murakata et al.
patent: 5063330 (1991-11-01), Leprince et al.
patent: 5461146 (1995-10-01), Lewis et al.
patent: 5475110 (1995-12-01), Hudkins et al.
patent: 5516771 (1996-05-01), Dionne et al.
patent: 5545636 (1996-08-01), Heath, Jr. et al.
patent: 5552396 (1996-09-01), Heath, Jr. et al.
patent: 5591855 (1997-01-01), Hudkins et al.
patent: 5594009 (1997-01-01), Hudkins et al.
patent: 5616724 (1997-04-01), Hudkins et al.
patent: 5621100 (1997-04-01), Lewis et al.
patent: 5621101 (1997-04-01), Lewis et al.
patent: 5654427 (1997-08-01), Dionne et al.
patent: 5672618 (1997-09-01), Heath, Jr. et al.
patent: 5705511 (1998-01-01), Hudkins et al.
patent: 5710145 (1998-01-01), Engel et al.
patent: 5808060 (1998-09-01), Hudkins et al.
patent: 238011 (1987-09-01), None
patent: WO 9402488 (1994-02-01), None
patent: WO 9707081 (1997-02-01), None
patent: WO 9721677 (1997-06-01), None
patent: WO 9807433 (1998-02-01), None
patent: WO 9947522 (1999-09-01), None
patent: WO 9962523 (1999-12-01), None
Grant & Hackh's Chemical Dictionary Fifth Edition (1969).*
Angeles, T.S., et al., “Enzyme-linked immunosorbent assay for trkA tyrosine kinase activity,”Anal. Biochem., 1996, 236(0130), 49-55.
Avruch, J., et al., “Raf meets ras: completing the framework of a signal transduction pathway,”TIBS, 1994, 19, 279-283.
Bottenstein, J.E., et al., “Growth of a rat neuroblastoma cell line in serum-free supplemented medium,”PNAS USA, 1979, 76(1), 514-517.
Corey, E.J., et al., “Synthesis of new lipoxygenase inhibitors 13-THIA- and 10- THIAARACHIDONIC acids,”Tett. Letters, 1985, 26(33), 3919-3922.
Denhardt, D.T., “Signal-transducing protein phosphorylation cascades mediated by Ras/Rho proteins in the mammalian cell: the potential for multiplex signalling,”Biochem. J., 1996, 318, 729.
Fearon, E.R., “Genetic lesions in human cancer”,Molecular Oncology, 1996, 143-178.
Flannery, et al., “Alkylation of disodioacetylacetone with halo ketals,”J. Org. Chem., 1972, 37(18), 2806-2810.
Fonnum, F., “A rapid radiochemical method for the determination of choline acetyltransferase,”J. Neurochem, 1975, 24, 407-409.
Glicksman, et al., “K-252a and staurosporine promote choline acetyltransferase activity in rat spinal cord cultures,”J. Neurochem, 1993, 61, 210-221.
Grove, D.S., et al., “Differential activation and inhibition of lymphocyte proliferation by modulators of protein kinase c: diacylglycerols, “rationally designed” activators and inhibitors of protein kinase C,”Experimental Cell Research, 1991, 193, 175-182.
Hart, L., et al., “Cyclopropane chemistry. VI. Acylation of some substituted cyclopropanes1,2,”J. Org. Chem., 1959, 24, 1261-1267.
Hawkins, et al., “Reactions of 1 : 2-dichloro-3 : 4-epoxybutane and related compounds,”J. Chem. Soc., 1959, 248-256.
Hershburg, R.N., et al., “ORSYAT,”Org. Syn., 1955, vol.. III, 626-631.
Kase, H., et al., “K-252a, a potent inhibitor of protein kinase C from microbial origin,”,J. Antibiotics, 1986, 39(8), 1059-1065.
Knochel, P., et al., “Preparaton and reactivity of highly functionalized organometallics at the α position of oxygen or nitrogen,”J. Org. Chem., 1993, 58, 588-599.
Kuehene, M.E., et al., “Studies in biomimetic alkaloid syntheses. 6. Alternative pathways to secodines and their acyclic enamino acrylate analogues. Total syntheses of desethylibophyllidine, D-norvincadifformine, desethylvincadifformine, 20-methyldesethylvincadifformine, and 3-oxovincadifformine,”J. Org. Chem., 1981, 46, 2002-2009.
Lehninger, A.L., “The molecular basis of cell structure and function,” Chapter 4,Biochemistry, Second Edition, Worth Publishers, Inc., 1975, 73-75.
Makara, G.M., et al., “An efficient synthesis of 5,7-dimethoxy-4-methylphthalide, a key intermediate in the synthesis of mycophenolic acid,”J. Org. Chem., 1995, 60, 5717-5718.
Martin-Zanca, D., et al., “Moecular and biochemical characterization of the human trk proto-oncogene,”Mol. Cell. Biol., 1989, 9, 24-33.
McManaman, J.L., et al., “Developmental discord among markers for cholinergic differentiation: In Vitro time courses for early expression and responses to skeletal muscle extract,”Developmental Biology, 1988, 125, 311-320.
Monia, B.P., et al., “Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase,”Nature Medicine, 1996 2(6), 668-674.
Paquette, L.A., et al., “First synthesis of cytotoxic 8,9-secokaurene diterpenoids. An enantioselective route to (−)-O-methylshikoccin and (+)-O-methylepoxyshikoccin,”J. Am. Chem. Soc., 1997, 119, 9662-9671.
Phelps, P.E., et al., “Generation patterns of four groups of cholinergic neurons in rat cervical spinal cord: a combined tritiated thymidine autoradiographic and choline acetyltransferase immunocytochemical study,”J. Comp. Neurol., 1988, 273, 459-472.
Pitt, A.M., et al., “High throughput screening protein kinase assays optimized for reaction, binding, and detection totally within a 96-well plate,”J. Biomol. Screening, 1996, 1(1), 47-51.
Reich, H.J., et al., “Organoselenium chemistry. Conversion of ketones to enones by selenoxide syn elimination,”J. Am. Chem. Soc., 1975, 97(19), 5434-5447.
Rotin, D., et al., “SH2 domains prevent tyrosine dephosphorylation of the EGF receptor: identification of Tyr992 as the high-affinity binding site for SH2 domains of phospholipase Cv,”EMBO J., 1992, 11, 559-567.
Smith, R.G., et al., “Trophic effects of skeletal muscle extracts on ventral spinal cord neurons in vitro: separation of a protein with morphologic activity from proteins with cholinergic activity,”J. Cell Biology, 1985, 101, 1608-1621.
Wood, J.L., et al., “Total synthesis of (+)-and (−)-K252a,”J. Am. Chem. Soc., 1995, 117, 10413-10414.
Xia, Z., et al., “Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis,”Science, 1995, 270, 1326-1331.
Zirkle, C.L., et al., The isomeric 3-Oxa- and 3-thiagranatanin-7-ols and their derivatives; reduction of bicyclic amino ketones related to tropinone1,2,J. Org. Chem., 1961, 26, 395-407.
Zha, Jiping, et al., “Serine phosphorylation of death agonist BAD in response to survival factor results in binding to 14-3-3 Not BCL-XL,” Cell, 1996, 87, 619-628.
Hudkins Robert L.
Reddy Dandu R.
Singh Jasbir
Tripathy Rabindranath
Underiner Ted
Cephalon Inc.
McKane Joseph K.
Wright Sonya
LandOfFree
Cyclic substituted fused pyrrolocarbazoles and isoindolones does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cyclic substituted fused pyrrolocarbazoles and isoindolones, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic substituted fused pyrrolocarbazoles and isoindolones will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3406425